<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100931">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02048059</url>
  </required_header>
  <id_info>
    <org_study_id>ANG1005-CLN-04</org_study_id>
    <nct_id>NCT02048059</nct_id>
  </id_info>
  <brief_title>ANG1005 in HER2+ Breast Cancer Patients With Progressive/Recurrent Brain Metastases</brief_title>
  <official_title>A Phase II, Open-Label, Multi-Center Study of ANG1005 in HER2+ Breast Cancer Patients With Progressive/Recurrent Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Angiochem Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Angiochem Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells
      in HER2+ breast cancer patients with recurrent brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See above.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Intracranial objective response rate</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of intracranial objective response</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median intracranial progression free survival (PFS)</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial PFS rates at 3, 6 and 12 months</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-month overall survival rate</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extracranial ORR</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with adverse events</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>On Day 1 of Cycles 1 and 3</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the drug concentration and distribution in the plasma. (AUC, Cmax, T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Upon enrollment through end of study period (1 year after last patient is enrolled)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>ANG1005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ANG1005</intervention_name>
    <arm_group_label>ANG1005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥ 18 years old

          2. Documented HER2+ breast cancer

          3. Recurrent/progressing brain metastases from breast cancer

          4. At least one radiologically-confirmed and measurable metastatic brain lesion -5.
             Prior treatment with whole brain radiotherapy (WBRT)

        6. Neurologically stable 7. Karnofsky Performance Status (KPS) score ≥ 80

        Exclusion Criteria:

          1. Known leptomeningeal disease

          2. Prior treatment with ANG1005/GRN1005

          3. Pregnancy or lactation

          4. Inadequate bone marrow reserve

          5. Any evidence of severe or uncontrolled diseases

          6. Patients with the presence of an infection including abscess or fistulae, or known
             infection with hepatitis B or C or HIV

          7. CNS disease requiring immediate neurosurgery intervention (e.g., resection, shunt
             placement, etc.)

          8. Known allergy to paclitaxel or any of its components
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Paul Castaigne, MD</last_name>
    <role>Study Director</role>
    <affiliation>Angiochem Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronica Burdusel, M.Sc. Pharm.</last_name>
    <phone>514-788-7800</phone>
    <phone_ext>206</phone_ext>
    <email>vburdusel@angiochem.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betty Lawrence</last_name>
    <phone>514-788-7800</phone>
    <phone_ext>205</phone_ext>
    <email>blawrence@angiochem.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurel R Chadde</last_name>
      <phone>312-695-1371</phone>
      <email>laurel.chadde@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Leanne Fountas</last_name>
      <phone>312-695-1342</phone>
      <email>leanne.fountas@northwestern.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Priya Kumthekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center Research</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith, RN</last_name>
      <phone>330-492-3345</phone>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Y Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univeristy of Texas Health Science Center in San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherie Noles</last_name>
      <phone>210-450-5964</phone>
      <email>nolesc@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Brenner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/22203732</url>
    <description>Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors</description>
  </link>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANG1005</keyword>
  <keyword>GRN1005</keyword>
  <keyword>LRP-1</keyword>
  <keyword>Targeted therapy</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Brain metastases</keyword>
  <keyword>Brain tumor</keyword>
  <keyword>Blood-brain barrier</keyword>
  <keyword>Trastuzumab</keyword>
  <keyword>Herceptin</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxol</keyword>
  <keyword>Breast cancer with brain metastases</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
